Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes MB-102 - CISMeF
Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes MB-102NCIt concept
Preferred Label : Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes MB-102;
NCIt synonyms : CD123-CD28-CD3zeta.EGFRt Autologous T Cells MB-102; CD123CAR-CD28-CD3zeta-EGFRt Lentiviral-transduced Autologous T Lymphocytes MB-102; Anti CD123-CAR/CD28-CD3zeta-EGFRt-expressing Autologous T Lymphocytes MB-102; Autologous CD123CAR-CD28-CD3zeta/EGFRt T Cells MB-102;
NCIt definition : A preparation of genetically modified autologous T-cells transduced with a replication
incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen
receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3
receptor alpha chain or IL3RA) and linked to the CD28 co-stimulatory signaling domain
fused to CD3 zeta, and a truncated form of the human epidermal growth factor receptor
(EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous
administration, the autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes
MB-102 are directed to and induce selective toxicity in CD123-expressing tumor cells.
CD123, a subunit of the heterodimeric interleukin-3-receptor (IL-3R), is normally
expressed on committed blood progenitor cells in the bone marrow; its overexpression
is associated with increased leukemic cell proliferation and aggressiveness. Devoid
of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates
detection of the administered T-cells in vivo and can promote elimination of those
cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC)
response.;